Skip to main content
. 2021 Aug 30;11(5):1763–1776. doi: 10.1007/s13555-021-00596-8

Fig. 4.

Fig. 4

Deucravacitinib and JAK 1/2/3 inhibitors’ pharmacokinetic parameters and whole blood IC50 values. BID twice daily, Cave average plasma concentration, Cmax maximum plasma concentration, Cmin minimum or trough plasma concentration, IC50 half-maximal inhibitory concentration, JAK Janus kinase, QD once daily, TYK2 tyrosine kinase 2